研究单位：[1]Fudan University[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[3]The 2nd affiliated hospital of Bengbu medical University,Bengbu,Anhui,China[4]The 2nd people's hospital of Anhui province,Hefei,Anhui,China[5]Fujian Cancer Hospital & Fujian Medical University Cancer Hospital,Fuzhou,Fujian,China[6]The 1st affiliated hospital of Xiamen University,Xiamen,Fujian,China[7]Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center,Shenzhen,Guangdong,China[8]The 4th affiliated hospital of Hebei Medical University,Shijiazhuang,Hebei,China[9]Anyang cancer hospital,Anyang,Henan,China[10]Henan Cancer Hospital,Zhengzhou,Henan,China[11]Wuhan University Zhongnan hospital,Wuhan,Hubei,China[12]Zhongnan University Xiangya Hospital,Changsha,Hunan,China[13]Huai''an first hospital,Huai''an,Jiangsu,China[14]Jiangsu cancer Hosipital,Nanjing,Jiangsu,China[15]Nantong cancer hospital,Nantong,Jiangsu,China[16]Yancheng the 3rd hospital,Yancheng,Jiangsu,China[17]The Northern Jiangsu People''s Hospital,Yangzhou,Jiangsu,China[18]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China[19]The 1st affiliated hospital of Nanchang University,Nanchang,Jiangxi,China[20]The 2nd affiliated hospital of Nanchang University,Nanchang,Jiangxi,China[21]The First Affiliated Hospital of Air Force Medical University,Xi''an,Shaanxi,China[22]Fudan University Shanghai cancer center,Shanghai,Shanghai,China,200032[23]Sichuan cancer hospital,Chengdu,Sichuan,China[24]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China[25]The 2nd affiliated hospital of Wenzhou medical university,Wenzhou,Zhejiang,China
研究目的：
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
